Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes

被引：25
作者：
Amrite, Aniruddha [2 ]
Pugazhenthi, Vidya [1 ]
Cheruvu, Narayan [3 ]
Kompella, Uday [1 ]
机构：
[1] Univ Colorado Denver, Aurora, CO 80045 USA
[2] Quinitles Inc, Clin Pharmacol, Overland Pk, KS 66211 USA
[3] Covidien, Clin Pharmacol, Hazelwood, MO 63042 USA
来源：
EXPERT OPINION ON DRUG DELIVERY | 2010年 / 7卷 / 05期
关键词：
ENDOTHELIAL GROWTH-FACTOR; TRANSSCLERAL DRUG-DELIVERY; BLOOD-RETINAL BARRIER; PROTEIN-KINASE-C; MACULAR DEGENERATION; RAT MODEL; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; BINDING CHARACTERISTICS; FACTOR EXPRESSION;
D O I：
10.1517/17425241003663236
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered in this review: This review discusses the pharmacological basis for using celecoxib, an anti-inflammatory drug capable of selectively inhibiting cycloxygenase 2, in treating AMD and DR. In addition, this article discusses the safety, delivery advantage and efficacy of celecoxib by transscleral retinal delivery, a periocular delivery approach that is less invasive to the globe compared with intravitreal injections. What the reader will gain: The reader will gain insights into the development of a pharmacological agent and a sustained release delivery system for treating DR and AMD. Further, the reader will gain insights into the influence of eye physiology including pigmentation and disease states such as DR on retinal drug delivery. Take home message: Transscleral sustained delivery of anti-inflammatory agents is a viable option for treating retinal disorders.
引用
收藏
页码：631 / 645
页数：15
相关论文
共 72 条
[1]   BINDING OF THE BETA-BLOCKERS TIMOLOL AND H 216/44 TO OCULAR MELANIN [J].
ABRAHAMSSON, T ;
BOSTROM, S ;
BRAUTIGAM, J ;
LAGERSTROM, PO ;
REGARDH, CG ;
VAUQELIN, G .
EXPERIMENTAL EYE RESEARCH, 1988, 47 (04) :565-577
[2]   Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit,and rat eyes [J].
Acheampong, AA ;
Shackleton, M ;
John, B ;
Burke, J ;
Wheeler, L ;
Tang-Liu, D .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :421-429
[3]   Formulation effects on ocular absorption of brimonidine in rabbit eyes [J].
Acheampong, AA ;
Small, D ;
Baumgarten, V ;
Welty, D ;
Tang-Liu, D .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2002, 18 (04) :325-337
[4]  
Aiello L P, 1997, Curr Opin Ophthalmol, V8, P19
[5]   Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies [J].
Aiello, LP .
OPHTHALMIC RESEARCH, 1997, 29 (05) :354-362
[6]  
Aiello LP, 1997, INVEST OPHTH VIS SCI, V38, P1647
[7]   Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor [J].
Aiello, LP ;
Bursell, SE ;
Clermont, A ;
Duh, E ;
Ishii, H ;
Takagi, C ;
Mori, F ;
Ciulla, TA ;
Ways, K ;
Jirousek, M ;
Smith, LEH ;
King, GL .
DIABETES, 1997, 46 (09) :1473-1480
[8]  
Alfaro D V., 2006, Age-related macular degeneration, P23
[9]   Transscleral drug delivery to the retina and choroid [J].
Ambati, J ;
Adamis, AP .
PROGRESS IN RETINAL AND EYE RESEARCH, 2002, 21 (02) :145-151
[10]   Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2,VEGF, and vascular leakage [J].
Amrite, AC ;
Ayalasomayajula, SP ;
Cberuvu, NPS ;
Kompella, UB .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (03) :1149-1160
12345678